Ongoing use of GLP-1 RAs may be limited by issues related to tolerability, efficacy, access, and cost. The boom in GLP-1 RAs has not gone unnoticed as this class of medication increased 300% from 2020 to 2022 and 3 different types of GLP-1 RAs have been under a drug shortage since 2024
p=0015
Microbiome 5:54
By not doing so, doctors also couldnt warn their patients of the potential exacerbation of their gastroparesis if they already were suffering from it so that they could make an informed decision about whether to take the drug By 2022, researchers additionally tied gallbladder issues to this class of drugs, which opened the door to the first round of lawsuits against manufacturers
The first, called de novo synthesis, involves the production of glutathione from three amino acids: glutamate, cysteine and glycine
Additional costs apply, including consultation, ongoing care, and side effect management